Phyllis Bellin is listed as an executive officer on 5 SEC Form D filings by 2 issuers between Jun 2009 and Sep 2016: Aevi Genomic Medicine, Inc. (Wayne, PA — biotechnology — 2009–2012; $28M reported sold to 88 investors) and Regenovation, Inc. (New York, NY — biotechnology — 2016; $1.38M reported sold to 10 investors).
What this means 2 separate companies raised money with this person listed as executive officer, over about 7 years. Across those companies the filings report $29.4M sold in total.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — 7 court cases matching the name, 9 bankruptcy cases matching the name listed in Key records below.
What this means 16 records came back, including 1 court case still open — open cases can take years and cost money. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 5 public filings for Phyllis Bellin and found 10 differences, 2 worth asking the sponsor about: 310% of the money raised went to insiders; Form D filed 400 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.